"Brodalumab (Psoriasis) - Forecast and Market Analysis to 2022" Now Available at Fast Market Research
Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide (Perera et al., 2012). Specifically, adult plaque psoriasis is the focus of this report and is defined using the 2013 International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnostic code L40.0. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and...
View full press release